

## Whole Blood Assay

Thymed's whole blood assay is exactly that – fresh whole blood, closely mimicking the in vivo scenario. The assay helps you define and visualize a wide variety of immune responses assisting in development of your novel vaccine, antibody therapeutic, biological or pharmaceutical. Useful for immunogenicity testing, immunotoxicology assessment and evaluation of antigen-specific immune responses, the assay provides crucial information for drug development as well as for regulatory authorities and enhances decision-making in all phases of clinical development.

Assays parameters available include but are not limited to:

- Viability (live/dead cell counts)
- Project-specific ELISAs
- Cellular immunophenotyping
- Immune cell activation assays
- Cell proliferation (CFSE)
- Intracellular cytokine staining (ICS)
- ELISpot analysis
- Microbead arrays (acute phase reactants, TH1/TH2 cytokines, chemokines, cardiovascular markers)

Thymed's whole blood assay was developed for assessing expected and unwanted immune responses in human donor or patient blood. The assay is limited only by the reagents available and as such has also been applied in murine and primate systems.

Located 45mins from Frankfurt International Airport, in the heart of Europe, Thymed boasts excellent logistics. Thymed's well-equipped, state-of-the-art laboratories and specialty testing services are ISO 9001 certified and conform to GLP.

### The Essentials

- **Material Requirements** – heparinized fresh whole blood from donors (can be provided by Thymed)
- **Volumes** – 40µl upwards
- Suitable for all **Discovery, Preclinical & Clinical Phases**
- Detects wanted/unwanted **Immunotoxicity, Immunogenicity** and **Immunosuppression**
- Enables detailed **Characterization** of immune response in a human ex vivo system
- Can be adapted for **High Throughput** drug screening
- Allows immunological comparisons of **Drug Variants, Biologics/Biosimilars** and **Vaccines Components**

